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Cellular/Molecular
Arrest of Myelination and Reduced Axon GrowthWhen
Schwann Cells Lack mTOR
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and Peter J. Brophy1
1Centre for Neuroregeneration, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom, 2Department of Neurogenetics, Max-Planck-Institute of
Experimental Medicine, 37075 Go¨ttingen, Germany, and 3Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR5239, IFR128, Universite´ de Lyon,
Ecole Normale Supe´rieure, 69364 Lyon Cedex 07, France
In developing peripheral nerves, differentiating Schwann cells sort individual axons from bundles and ensheath them to generate
multiple layers of myelin. In recent years, there has been an increased understanding of the extracellular and intracellular factors that
initiate and stimulate Schwann cell myelination, together with a growing appreciation of some of the signaling pathways involved.
However, our knowledge of how Schwann cell growth is regulated during myelination is still incomplete. The mammalian target of
rapamycin (mTOR) is a core kinase in two major complexes, mTORC1 and mTORC2, that regulate cell growth and differentiation in a
variety ofmammalian cells. Here we show that elimination ofmTOR frommurine Schwann cells prevented neither radial sorting nor the
initiation of myelination. However, normal postnatal growth of myelinating Schwann cells, both radially and longitudinally, was highly
retarded. The myelin sheath in the mutant was much thinner than normal; nevertheless, sheath thickness relative to axon diameter
(g-ratio) remained constant in both wild-type andmutant nerves from P14 to P90. Although axon diameters were normal in the mutant
at the initiation of myelination, further growth asmyelination proceeded was retarded, and this was associated with reduced phosphor-
ylation of neurofilaments. Consistent with thinner axonal diameters and internodal lengths, conduction velocities inmutant quadriceps
nerves were also reduced. These data establish a critical role for mTOR signaling in both the longitudinal and radial growth of the
myelinating Schwann cell.
Introduction
Myelinating Schwann cells in themammalian peripheral nervous
system (PNS) reach the promyelinating stage when they have
adopted a one-to-one relationship with axons after sorting them
to the periphery of axon bundles (Peters and Muir, 1959; Jessen
and Mirsky, 2005; Sherman and Brophy, 2005). Schwann cell
proliferation during development is required for individual axon
ensheathment and is stimulated by axonal neuregulin (Nrg1),
acting via ErbB2/3 receptors (Martin andWebster, 1973;Webster
et al., 1973; Wood and Bunge, 1975; Salzer et al., 1980; Stewart et
al., 1993; Morrissey et al., 1995; Riethmacher et al., 1997). The
Nrg1/ErbB system is also a key regulator of myelination and re-
myelination after injury (Michailov et al., 2004; Nave and Salzer,
2006; Newbern and Birchmeier, 2010; Fricker et al., 2011), al-
though it is not essential for maintenance of the mature sheath
(Fricker et al., 2011).
ErbB receptors can act through a variety of cytoplasmic signaling
pathways. In Schwann cells, they activate the phosphatidylinositol-
3-kinase (PI3K)/Akt pathway (Maurel and Salzer, 2000; Li et al.,
2001). Phosphatidylinositol 3,4,5-trisphosphate, the product of
PI3K, is hydrolyzed by the lipid phosphatase and tensin homolog
(PTEN), and ablation of the gene causes hypermyelination in both
the CNS and PNS (Goebbels et al., 2010). In the PNS, Dlg1 is be-
lieved to stabilize PTEN, thus potentiating the ability of PTEN to
modulatemyelin growth (Cotter et al., 2010). Nevertheless, overex-
pression of a constitutively active formof Akt enhancesmyelination
in theCNSbuthasnoeffectonPNSmyelination (Flores et al., 2008).
Themammalian target of rapamycin (mTOR) kinase is a down-
stream effector of PI3K signaling and functions in two major com-
plexes, mTORC1 and mTORC2, to regulate cell growth and
differentiation in a variety of mammalian cells (Zoncu et al.,
2011). There is considerable evidence that mTOR has a role
in regulating myelination in the CNS (Bibollet-Bahena and
Almazan, 2009; Narayanan et al., 2009; Tyler et al., 2009, 2011;
Goebbels et al., 2010). The mTORC1 and mTORC2 complexes
include the specific regulatory proteins raptor and rictor, respec-
tively, and act through distinct if overlapping signaling pathways
(Zoncu et al., 2011). Although once considered to be rapamycin-
insensitive, mTORC2 can be inhibited by long-term treatment
with rapamycin, and this occurs in oligodendrocytes in culture
(Sarbassov et al., 2006; Tyler et al., 2011). Nevertheless, it is not
yet knownwhether rapamycin treatment of intact animals inhib-
its both complexes in oligodendrocytes, or whether the effects
Received Sept. 21, 2011; revised Nov. 3, 2011; accepted Nov. 24, 2011.
Author contributions: D.L.S. and P.J.B. designed research; D.L.S., M.K., and L.-M.W. performed research; K.-A.N.
and Y.-G.G. contributed unpublished reagents/analytic tools; D.L.S., M.G., K.-A.N., Y.-G.G., and P.J.B. analyzed data;
D.L.S. and P.J.B. wrote the paper.
This study was supported by theWellcome Trust and the Novartis Foundation. We thank Heather Anderson and
Stuart Flemingof EdinburghUniversity for excellent technical assistance andDr. Dominique Langui of the ICMCentre
de Recherche, CHU Pitie´-Salpeˆtrie`re, Paris for EM access and assistance.
Correspondence should be addressed to Peter J. Brophy, Centre for Neuroregeneration, University of Edinburgh,
Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK. E-mail: Peter.Brophy@ed.ac.uk.
DOI:10.1523/JNEUROSCI.4814-11.2012
Copyright © 2012 the authors 0270-6474/12/321817-09$15.00/0
The Journal of Neuroscience, February 1, 2012 • 32(5):1817–1825 • 1817
observed in the CNS are the consequence
of influencing mTOR function in both
neurons and glia.
Here, we have used a conditional gene
inactivation approach to ask whether ab-
lating mTOR function specifically in
Schwann cells influences their ability to
myelinate. Thus, we eliminate uncertainty
over the target cell and can be sure that
both mTORC1 and mTORC2 are dis-
rupted. Further, rictor can still function
outside the TORC2 complex, where it can
stimulate phosphorylation at S473 of Akt
by interacting with integrin-linked kinase
(ILK) (McDonald et al., 2008). We show
that in mutants, the myelin sheath is thin,
Schwann cells do not elongate normally,
and the radial growth of axons is compro-
mised with collateral effects on axon di-
ameter and nerve function. We propose
that signaling through the mTOR com-
plexes has a critical role in regulating both
myelin thickness and overall Schwann cell
growth during myelination.
Materials andMethods
Mice and genotyping. All animal work con-
formed to UK legislation (Scientific Proce-
dures) Act 1986, and to the University of
Edinburgh Ethical Review Committee policy.
Cnp1-Cremice have been described previously
and have been shown to be effective in promot-
ing Cre-mediated recombination in mouse
embryonic peripheral nerves (Lappe-Siefke et
al., 2003; Grove et al., 2007). Mice carrying an
mTOR floxed allele where one LoxP site was
upstream of the promoter and the second site
was in the intron preceding exon 6 and their
use to inactivatemTOR in skeletal muscle have
been described previously (Gangloff et al.,
2004; Risson et al., 2009). Both Cre and floxed
mouse lines were back-crossed to a minimum
of F8 with C57BL/6 mice. Genotyping of the recombined allele by PCR
used the primers 5-TTCATTCCCTTGAAAGCCAGTCTCACC-3 and
5-TCATTACCTTCTCATCAGCCAGCAGTT-3, and was predicted to
yield a product of 552 bp from the recombined allele (Gangloff et al.,
2004).
Histology, immunostaining, andWestern blotting.The perineuriumwas
removed from all peripheral nerves before immunostaining of teased
fibers or Western blotting. Further preparation and the method for im-
munostaining of cryosections or teased fiber preparations was as de-
scribed previously (Sherman et al., 2005; Grove et al., 2007). Primary
antibodies were rabbit unless specified otherwise and were used at the
following dilutions for immunostaining or Western blotting, as indi-
cated; all were from Cell Signaling Technology unless otherwise noted:
anti-mTOR (catalog no. 2983, 1:200 for immunostaining, 1:1000 for
Western blotting), anti-phosphoS235/236-S6 (catalog no. 4858, 1:100
for immunostaining, 1:1000 for Western blotting), anti-S6 (catalog no.
2217, 1:1000), anti-S473 phospho-Akt (catalog no. 4058, 1:1000), anti-
myelin-associated glycoprotein (anti-MAG; 1:3000; a gift fromDr.David
Colman, McGill University, Montreal, Quebec, Canada), mouse mono-
clonal anti-S473 phospho-Akt (catalog no. 4051, 1:1000), anti-T308
phospho-Akt (catalog no. 2965, 1:1000), anti-Akt (catalog no. 9272,
1:1000), anti-phospho T37/46–4E-BP1 (catalog no. 2855 1:1000), anti-
4E-BP1 (catalog no. 9644, 1:1000), anti-Krox20 (1:100 for immunostain-
ing, 1:500 for Western blotting; Covance), anti-Nrg1 (catalog no.
SC-348, 1:300; Santa Cruz Biotechnology); anti-Sox10 (1:1000; a gift
from Dr. Michael Wegner, University of Erlangen, Bavaria, Germany),
chicken anti-Po (1:200 for immunostaining, 1:2000 forWestern blotting;
Aves Labs), mouse monoclonal anti-DLG1 (1:1000; Enzo Life Sciences),
anti-radixin (raised against the peptide DKYKTLRQIRQGNTK, 1:400),
mouse monoclonal anti-neurofilament H, SMI-34 (1: 1000; Covance)
and SMI-32 (1:400; Covance). All other primary and secondary anti-
bodies and nuclear stains were described previously (Sherman et al.,
2005; Grove et al., 2007). Conventional fluorescence microscopy was
performed using an Olympus BX60 microscope and images were cap-
tured using a Hamamatsu Orca-ER camera and Improvision Openlab
software. For confocal microscopy, we used a Leica TCL-SL confocal
microscope with either a 40 or a 63 objective, 1.4 NA, and Leica
proprietary software. The acquired stacks were assembled using the
maximum projection tool and all figures were prepared using Adobe
Photoshop CS4 extended version 11. Western blotting was performed
as described previously (Sherman et al., 2005) on P21 sciatic nerve
lysates containing phosphatase inhibitors. For electron microscopy,
mice were perfused intravascularly with 2.5% glutaraldehyde and 4%
paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4. Nerves
were removed, fixed for 2 h at room temperature then for 18 h at 4°C
in the same fixative, postfixed in OsO4, and embedded in Araldite.
Ultrathin sections were stained with uranyl acetate and lead citrate
and examined on a Phillips BioTwin CM120 electron microscope
Figure 1. Conditional inactivation of mTOR in Schwann cells. A, PCR of genomic DNA isolated from mTORflox/flox and mutant
quadriceps nerves shows efficient recombination in mutant nerves. B, Immunofluorescence analysis of P21 teased individual
quadriceps nerve fibers confirms the loss of mTOR from the cytoplasm of Schwann cells in the mutant. The Schwann cell nucleus
stained with TOTO-3 is in blue and mTOR is in green. Scale bar, 10m. C, Western blot analysis of lysates from P21 sciatic nerve
shows thatmTORprotein is reduced in themutant and that themTORdownstream targets S6 and 4E-BP1 are less phosphorylated.
In contrast, there is a substantial increase in phosphorylation at T308 of Akt, and no decrease in phosphorylation at S473 of Akt.
Gamma-actinwas the loading control.D, Immunofluorescence staining of P21 teasedquadriceps nerve fibers confirmed the loss of
phospho (P)-S6 in Schwann cells lackingmTOR.Myelinwas visualizedusing antibodies against Po in red, phospho-S6 in green, and
Schwanncells nucleiwere stainedwithTOTO-3. Scalebar, 10m.E, Nerve conductionvelocities in thequadricepsnervesof control
and mutant mice are represented in a vertical scatter plot. Each point is the mean of measurements from both nerves from
one mouse; eight mice were analyzed. Horizontal lines are the SEMs and p 0.005. F, Rotarod testing was at two speeds
of rotation; mutant mice were significantly worse at both speeds. Values are expressed as mean time to fall SEM (n
6, *p 0.05, **p 0.005).
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equipped with either a Gatan Orius or an Olympus Morada digital
camera.
Electrophysiology and rotarod. Acutely prepared quadriceps nerves,
taken from 42-day-old control andmutant mice, were placed in oxygen-
ated mammalian HEPES physiological solution (137 mM NaCl, 5 mM
KCl, 2 mM CaCl, 1 mM MgCl, 5.5 mM D-glucose, and 5 mM HEPES, pH
7.2–7.4) and nerve conduction velocities measured as described previ-
ously (Court et al., 2004). Rotarod analysis of mice at P42 (minimum of
three per group)was performed at twodifferent speeds, 24 and 32 rpm, as
previously described (Court et al., 2004), except mice were conditioned
for 2 d.
Morphometry. Quantitation of the relative numbers of Sox10- and
Krox20-positive Schwann cells at P21 was performed on longitudinal
cryosections of quadriceps nerves and aminimum of 300 Sox10-positive
Schwann cells was counted in each of two animals per condition. Quan-
titation of the absolute numbers of Sox10-positive Schwann cells in the
quadriceps nerves from control and mutant animals was performed on
cross-sections and a minimum of five sections per animal (five animals
per genotype) were counted. Cross-sectional areas of 0.5 m toluidine
blue-stained sections of nerve, excluding the perineurium, were mea-
sured using ImageJ after construction of montages of images in Photo-
shop captured at 100. The numbers of sorted, promyelinated, and
myelinated axons were quantitated in cross-sections using montages of
electronmicrographs assembled in Photoshop. Aminimumof 200 axons
were counted per animal, with a minimum of three animals per condi-
tion. The diameters of axons and axons plus myelin were measured in
electron micrographs by first measuring the circumference of each by
hand-tracing using ImageJ, then by calculating areas from which diam-
eters were derived. Their g-ratios were calculated from these diameters. A
minimum of 100 axons was counted per animal and aminimum of three
Figure 2. Mutant Schwann cells sort axons and differentiate, but their nerves are abnormally small.A, Electronmicrographs of cross-sections of quadriceps nerves from floxedmTOR andmutant
miceatP2, a timewhenaxon sorting is normallywell advanced, showed that formationof 1:1promyelinating figureswasnormal inmutantmice. Scalebar, 5m.B,C, Immunofluorescence staining
of longitudinal sections of quadriceps nerves with antibodies against Sox10 (for all Schwann cells) and Krox20 (transcription factor required for progression beyond the promyelinating stage) and
quantitation revealed no difference in double-labeled Schwann cells between floxed mTOR andmutant mice at P21, showing that loss of mTOR did not prevent Schwann cell differentiation. Scale
bar, 20m.D,Western blot of sciatic nerve lysates showing no decrease in Krox20, Dlg1, or the active cleaved fragment of axonal Nrg1 in themutant but reduced amounts of themyelin protein P0.
Gamma-actin was the loading control. E, F, Electron micrographs of quadriceps nerves at P21 show that the cross-sectional area of mutant nerves is much smaller than normal, which may explain
why the density of Schwann cells revealed by Sox10 staining in the mutant shown in C appears to be increased. The decreased cross-sectional area was first significant at P7 and became more
pronounced with age (means SEM, n 3, **p 0.01, ***p 0.001). Scale bar, 20m.
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animals was used per condition. Internodal
lengths were measured as described using
Openlab (PerkinElmer) (Court et al., 2004).
Statistical analysis. Statistical analysis was by
unpaired t tests with Graphpad Prism 5.0c
software.
Results
Conditional inactivation of mTOR in
Schwann cells
We generated mice without functional
mTOR in Schwanncells as described inMa-
terials and Methods, above, by crossing
mice homozygous for a floxed allele of
mTOR (Risson et al., 2009)with aCnp1-Cre
driver line specific for myelin-forming glia
(Lappe-Siefke et al., 2003). Cre-mediated
inactivation of thismTORflox/floxmouse line
(control mice or floxed mTOR mice) has
previously been shown to abrogate mTOR
expression efficiently in skeletal muscle
(Risson et al., 2009), and the Cnp1-Cre
driver line is effective in Schwann cells dur-
ing embryonic development before the ra-
dial sorting of axons (Grove et al., 2007).
Throughout this paper, we refer to mice
with the genotype mTORflox/flox/Cnp1-
Cre/ asmTORmutants. TheDNA frag-
ment generated by PCR of peripheral
nerve genomic DNA after Cre-mediated
recombination showed effective inactiva-
tion of the mTOR gene (Fig. 1A). Loss of
mTOR in Schwann cells was confirmed by immunofluorescence
and the substantial decrease inmTOR protein observed byWest-
ern blotting of peripheral nerve lysates (Fig. 1B,C). Persistence of
residual mTOR protein in nerve lysates is best explained by the
fact that sciatic nerves contain, in addition to Schwann cells, cap-
illary endothelial cells and fibroblasts, and axons (Fig. 1B).
Ribosomal S6 kinase (S6K) is a downstream target of
mTORC1 and the reduced phosphorylation of one of its sub-
strates, the ribosomal S6 protein, indicated that the mTORC1
pathway was no longer active (Fig. 1C,D). The percentage of
Schwann cells immunopositive for phospho-S6 at P21 was re-
duced from 100% in the control to 1% in the mutant nerves,
which attests to the efficiency ofCnp1-Cre-mediated recombina-
tion and ablation of mTOR expression. Phosphorylation of a
second well characterized target of mTORC1, the eukaryotic ini-
tiation factor 4E-BP1, was also substantially reduced (Fig. 1C).
Phosphorylation of Akt at S473 is a downstream target of
mTORC2 signaling (Sarbassov et al., 2005), but can also be me-
diated in an mTOR-independent fashion by the ILK/rictor com-
plex (McDonald et al., 2008). Indeed, we did not observe a
decrease in phospho-S473Akt inmutant sciatic nerve lysates (Fig.
1C) and we did observe enhanced phosphorylation at the T308
site (Fig. 1C). Blotting for the latter epitope suggested that there
were two species of Akt phosphorylated at T308 that migrated
close together (Fig. 1C), and successive incubation with antibod-
ies that recognized S473 then T308 indicated that the major up-
per band was doubly phosphorylated at both sites, whereas the
lower band was singly phosphorylated at T308 (data not shown).
Mutant mice were born in predicted numbers and were no
different in weight from controls up to P90. At birth they were
indistinguishable from littermates and displayed no overt clinical
phenotype. Nevertheless, the nerve conduction velocities of mu-
tant nerves were severely reduced from 38.7 0.7 m/s to 11.7
1.5 m/s (n  8,  SEM, p  0.005; Fig. 1E). Analysis of motor
behavior revealed that these reduced conduction velocities were
associated with poorer performance in the Rotarod test (n  3,
p 0.05 at 24 rpm, p 0.005 at 32 rpm; Fig. 1F).
Loss of mTOR retards myelination
We have previously shown in wild-type nerves that by P3 there is
extensive radial sorting with the establishment of a one-to-one
relationship of Schwann cells with axons at this so-called promy-
elination stage (Grove et al., 2007). Radial sorting of axons in
mutant nerves was normal at P2 (Fig. 2A); Schwann cell differ-
entiation was also unimpaired, as shown by the normal percent-
age of Schwann cells that were both Sox10 and Krox20 in the
mutant at P21 (Fig. 2B,C). The amount of Krox20 protein in P21
sciatic nerve lysates, as assessed by Western blot, was not de-
creased either; if anything, it was slightly increased (Fig. 2D). In
contrast, there was a decrease in the amount of themajor periph-
eral myelin protein P0, suggesting a deficit in myelin production
(Fig. 2D). The increase in Krox20 levels was likely due to the fact
that there was a 1.9-fold increase in the number of Sox10
Schwann cells from 38.9 1.1 to 73.1 2.5 in cross-sections of
the mutant nerve at P21 (values are means  SEM, n  5, p 
0.0001). This increase in Schwann cell number probably also
accounts for the fact that there was a slight increase in the amount
of the mammalian discs large homolog 1 protein (Dlg1), a pro-
posed negative regulator of myelination (Cotter et al., 2010). Ap-
propriate signaling from the axon was indicated by the fact that
Nrg1 levels were not reduced (Fig. 2D). Nevertheless, there was a
dramatic reduction in the cross-sectional area of mutant nerves
(Fig. 2E), whichwas first significant at P7 (values are SEM, n
Figure3. Myelination is delayed in the absence ofmTOR in Schwann cells.A,B, Electronmicroscopy revealed a large number of
sorted but unmyelinated, promyelinating profiles at P21. When quantitated, the difference in the number of promyelinated
profiles as a percentage of all sorted axons was significantly higher in mutant quadriceps nerves from P2 to P42 (means SEM,
n 3, **p 0.01, ***p 0.001). However, by P90, the percentage of unmyelinated axons in the mutant had declined to 5%.
Scale bar, 2 m. C, Vertical scatter plots of quadriceps axonal diameters for promyelination-stage axons in three independent
control mice (1–3) and three mutant mice (4–6) at P42. All the control values were1.3m. However, in the mutant, many
large axons were sorted into a 1:1 relationship with Schwann cells that had still not myelinated (4–6). The median values for
animals 4, 5, and 6 were 1.7, 1.9, and 1.9m respectively.
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3, p 0.01 at P7, P14, andP21; p 0.001 at P42 andP90; Fig. 2F).
To account for the reduced size of peripheral nerves in the mu-
tant, we first asked whether myelination occurred normally. Un-
myelinated promyelinating figures were more numerous in
mutant nerves compared with floxed mTOR mice (Fig. 3A,B),
indicating a delay in the progression of myelination. Neverthe-
less, promyelinating Schwann cells were associated with a wide
range of low to large caliber axons (Fig. 3C) and 95% of all sorted
axons were ultimately myelinated by P90 (Fig. 3B). Hence, the
delay in initiating myelin deposition in a fraction of the sorted
axons was not because they were of an unusually small diameter.
Mutant nerves have thinner myelin and reduced axon
diameter
The fact that the reduced nerve growth in the mutant only be-
came apparent with age and after the bulk of axon sorting had
occurred suggested that either myelination did not proceed nor-
mally or radial growth in axon diameter was impaired, or both.
Electron microscopy revealed that, consistent with the reduced
amount of P0 protein (Fig. 2D), myelin in the mutant was con-
sistently thinner than normal; this aberrant ensheathment per-
sisted from P7 until P90 (Fig. 4).
Quantitation of the g-ratio at different
ages revealed that the growth of the my-
elin sheath, relative to axon diameter, was
not only retarded (Fig. 5A) but was also
arrested (Fig. 5B). Although the mean
g-ratio of the mutant nerves was always
significantly different to control at each
age (p 0.005; Fig. 5B), there was no sig-
nificant change in the g-ratio of mutant
nerves fromP14 to P90, as was the case for
controls (Fig. 5B). Hence, similar to the
g-ratio during normal myelination, the
abnormal ratio inmutant nerveswas set at
an early age and did not change as the
mice matured (Fig. 5B).
Plots of g-ratio versus axon diameter
(Fig. 5A) indicated that mutant axons
were of reduced caliber, although these
were not significantly different from con-
trols until P21 (Fig. 5C), a time when
75% of sorted axons in the mutant were
already myelinated (Fig. 3B). Reduced
axon caliber in dysmyelinating mouse
mutants has previously been shown to be
attributable to abnormal axonal interac-
tions with ensheathing Schwann cells in
the PNS and oligodendrocytes in the CNS
and to be associated with reduced neuro-
filament phosphorylation (de Waegh et
al., 1992; Kirkpatrick and Brady, 1994;
Brady et al., 1999; Martini, 2001). In
agreement with this, we found substantial
deficits in the phosphorylation of neuro-
filament H in the axons of mutants (Fig.
6A).NeurofilamentH is known to be cru-
cial in the development of large axons
(Elder et al., 1998) and phosphorylation
is believed to regulate axonal caliber
through its effect on neurofilament pack-
ing (Cole et al., 1994). Consistentwith this
view, large unmyelinated mutant fibers
displayed a high density of axonal cytoskeletal elements, includ-
ing neurofilaments (Fig. 6B). It has been proposed that theMAG
might act as a key molecule in signaling between Schwann cells
and their ensheathed axons because the peripheral nerves of
MAG-deficient mice show reduced axonal calibers, decreased
neurofilament spacing, and reduced neurofilament phosphory-
lation, even though they myelinate normally (Yin et al., 1998). It
seems unlikely that deficiencies in MAG-mediated signaling
caused reduced axonal caliber, since mTOR mutant peripheral
nerves were actually enriched in MAG compared with controls
(Fig. 6A). This was likely due to the fact that MAG in peripheral
nerves is predominantly localized to noncompactmyelin, includ-
ing the periaxonal membrane apposed to the axon (Trapp and
Quarles, 1982).
Aberrant growth including short internodes in the absence
of mTOR
In addition to arrested radial growth, mutant Schwann cells also
displayed reduced longitudinal growth (Fig. 7A,B). Internodes in
mutant quadriceps nerves at P21 showed a wider range of lengths
compared with control nerves and mean values were reduced
Figure 4. Myelin produced bymTORmutant Schwann cells is thinner than normal and stays thin during development. Electron
micrographs of cross-sections of quadriceps nerves shows sorted axons inmutant nerves but thinmyelin fromP7 to P90. Scale bar,
5m.
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from 488  12.9 m to 241  17.8 m
(SEM, n 3). Consistent with this 50%
reduction in intermodal length, there was
a 1.9-fold increase in the number of
Schwann cells inmutant nerves compared
with controls (see Loss of mTOR retards
myelination, above). Other derangements,
such as myelin outfoldings, were also ob-
served at low frequency in the mutant
from P7 onwards but not in controls (Fig.
7C). However, these were not associated
with a decrease in Dlg1 expression (Fig.
2D), as has been proposed in othermouse
models (Cotter et al., 2010). In unmyeli-
nated, large diameter axons, in addition to
some vacuolation and redundant basal
lamina, we commonly observed that the
axonal membrane was highly irregular in
outline (Figs. 6B, 7D).
Discussion
We have shown by inactivating the mTOR
gene that mTOR signaling plays a central
role in regulating the growth of the myelin
sheath in the PNS.Mice with Schwann cells
lacking mTOR displayed reduced rates of
nerve conduction associated with impaired
performance in the rotarod test, whichwere
consistentwithacombinationof smaller ax-
onal calibers and shorter internodal length
(Court et al., 2004). The Cnp1-Cre driver
linewould also be expected to ablatemTOR
expression in oligodendrocytes and the def-
icits in motor function might also have
resulted in derangements in the CNS.
However, althoughbeyond the scope of this
work, preliminary analysis of the CNS did
not reveal the dramatic hypomyelination
that we observed in the PNS.
Mutant Schwann cells were able to sort
axons from bundles to adopt the 1:1 rela-
tionship characteristic of the promyelinating stage and most sorted
axons were eventually myelinated. Expression of Krox20, a tran-
scription factor known to be required for progression beyond the
promyelinating stage (Topilko et al., 1994),was consistentwith cells’
ability toproliferate,differentiate, andmyelinate.Akey featureof the
cell biologyofmTORmutantSchwanncells is that theyproduce thin
myelin and short internodes. Further, the fact that the extent of
myelin ensheathment relative to axon caliber as measured by the
g-ratio does not change in themutant fromP14 toP90 suggests that,
as in control animals, the g-ratio is still set at an early stage ofmyeli-
nation. Nevertheless, normal levels of Nrg1 in the mutant suggest
that signaling from the axon is not deficient.
Work on the Trembler dysmyelinating mutant has strongly
implicated neurofilament phosphorylation and its predicted in-
fluence on filament packing density as determining reduced axon
caliber, and evidence for a relationship between neurofilament
phosphorylation and axon size has also been found in a human
peripheral neuropathy, CMT1A (de Waegh et al., 1992; Watson
et al., 1994). Schwann cellMAGhas been proposed as a key aspect
of the signal regulating neurofilament phosphorylation (Yin et
al., 1998); however, we did not observe reduced levels of MAG in
mTOR mutant nerves.
How might the absence of mTOR influence the growth of
Schwanncells duringmyelination?Well characterizeddown-stream
targets of mTORC1 are the eukaryotic initiation factor 4E-BP1 and
the ribosomal S6K, both of which regulatemRNA translation (Rus-
sell et al., 2011). Stimulation of TORC1 causes phosphorylation of
4E-BP and the release of a second initiation factor, eIF4E, which
promotes translation (Fingar et al., 2002). ActivationofTORC1also
activates S6K, which phosphorylates several substrates known to be
involved in translation initiation, including a regulatory subunit
(eIF4B)ofRNAhelicase (Holz et al., 2005). Interestingly, rapamycin
does not always inhibit 4E-BP1 phophorylation, despite efficiently
preventingS6Kactivity (Chooetal., 2008;Feldmanetal., 2009).This
suggests that rapamycin-mediated inhibition of mTORC1may not
always be a reliable way to investigate downstream pathways.
We have shown that phosphorylation of both 4E-BP1 and S6
is highly reduced in the mutant; hence, it seems possible that
compromised rates of protein synthesis might contribute to im-
paired myelin growth and Schwann cell elongation. This might
also explain why myelinating Schwann cells, which actively ex-
tend both longitudinally and radially, could be particularly vul-
nerable to mTOR ablation compared with other cell types in the
nerve that also express mTOR. However, the possibility that
Figure 5. Mutant nerves have thin myelin and reduced axon diameters. A, B, Quantitation of g-ratios as a function of axon
diameter from P14 to P90 indicated strong diversion of the regression lines through the data for control compared with mutant
quadriceps nerves,whichwas confirmedby analysis ofmean values SEM (n3). At each age, therewas a significant difference
between control and mutant (**p 0.05, ***p 0.005). However, there was no significant difference between the g-ratios
measured at P14 and P90 for control nerves or between g-ratios measured at P14 and P90 for mutant nerves. C, Panel A indicated
that therewere fewer large caliber axons in themutant at older ages. This was confirmed bymeasuringmean axonal diameters SEM
(n 3) for control andmutant. A significant reduction in axonal diameter in themutantwas found fromP21onwards (**p 0.01).
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other functions known to involvemTORmight also be affected in
Schwann cells cannot be excluded. Mitochondrial energy metabo-
lism and mitochondrial biogenesis are downstream targets of
mTORC1(Chenet al., 2009), anddisruptionofmitochondrial func-
tion through inactivation of the mitochon-
drial transcription factor Tfam has recently
been shown to cause demyelination and ax-
onal deficits (Viader et al., 2011). Further,
since lipids comprise 76% by weight of the
peripheral myelin sheath (O’Brien et al.,
1967), dysregulation of lipid biosynthesis
woulddisruptmyelin accumulationand the
mTORC1 complex regulates SREBP, a key
protein in the control of lipogenesis (Peter-
sonet al., 2011). Indeed,Krox20andSREBP
synergistically regulate lipogenesis in
Schwann cells (Leblanc et al., 2005). A pos-
sible role for dysregulation of autophagy is
alsopossible,basedonrecent studiesonmy-
elination in vitro using dorsal root ganglion
explant (DRG) cultures from mutant mice
(Rangaraju et al., 2010). The unc-51-like ki-
nase, a component of the autophagy com-
plex, is phosphorylated bymTORC1 which
inhibits autophagy (Wullschleger et al.,
2006).Rapamycinhasbeen shown to rescue
myelination inDRG cultures frommice ex-
pressing a mutant form of the myelin pro-
tein PMP22, and this has been attributed to
inhibition ofmTOR function and concom-
itant activation of autophagy (Rangaraju
et al., 2010): nevertheless, no enhance-
ment of myelin synthesis was observed in
rapamycin-treated explants from wild-type
animals. Finally, the actin-based cytoskele-
ton is a target of mTORC2 and Schwann
cells lacking N-WASP, a regulator of actin
dynamics, produce thin myelin (Jacinto et
al., 2004; Jin et al., 2011; Novak et al., 2011).
In the CNS, rapamycin treatment of
mice reverses hypermyelination caused by
expression of a constitutively active form of
Akt in oligodendrocytes (Flores et al., 2008;
Narayanan et al., 2009). Although rapamycin did not affect the ex-
tent of myelination in the CNS of adult wild-type mice, it did cause
modest reductions in the levels of CNS myelin proteins in younger
Figure 6. Mutant nerves have reduced neurofilament phosphorylation and high neurofilament packing density. A, At P21, there is a significant difference in axonal caliber between control and mutant
quadriceps axons (Fig. 5C).Western blotting of sciatic nerve lysates at the same age showed amajor decrease in the extent of neurofilament H phosphorylation, as determined by the antibody SMI-32,which
recognizesanepitopenormallymaskedbyphosphorylationandwhichisuncoveredondephosphorylation.OtherphosphorylatedepitopesrecognizedbytheantibodySMI-34wereunaffected,andMAGwasnot
reduced.Tubulinandactinwere loadingcontrols.B, ElectronmicrographofmutantquadricepsatP90showsthe increaseddensitywithinapromyelinatingaxon(diameter,3.1mbesideamyelinatedaxonof
comparable diameter, 3.3m). Scale bar, 1m.
Figure7. Mutantnerveshaveshorter internodesandaberrantmyelin.A,B, Immunofluorescence imaging(A)ofa teasedmutant fiber
using an antibody against radixin (green), which is concentrated atmicrovilli, and TOTO-3 to visualize Schwann cell nuclei (blue). Arrows
indicate the position of nodes of Ranvier. This reveals some variability in internodal length, which is quantitated in the histogram (B)
showing the frequency distribution of internodal length in control andmutant quadriceps nerve. Scale bar, 50m. C,D, Electronmicro-
graphs of aberrant profiles frommutant nerves observed at all ages fromP90. Outfoldings of thinmyelin are shown in C. Arrows point to
redundantbasal laminawithvacuolation intheSchwanncell cytoplasmsurroundinganunmyelinatedaxon.Scalebars:C, 2m;D, 1m.
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animals (Narayanan et al., 2009). Also, it has been shown that mice
with mutations in either neuronal TSC1 or TSC2 (inhibitors of
mTORC1),whichare associatedwithhypomyelination, arepartially
rescued by rapamycin treatment (Meikle et al., 2008), and rapamy-
cin treatment of purified oligodendrocytes or their precursors has
revealed a role for mTOR in the differentiation of oligodendrocyte
precursors (Tyler et al., 2009).Translationof the transcription factor
Olig2 appears to be a likely target responsible for this effect on dif-
ferentiation (Narayanan et al., 2009). Recently, it has been shown
that eliminating the activator of mTORC1, Rheb1, in both neurons
and glia leads to a substantial reduction in the amounts of CNS
myelin proteins and myelin sheath, whereas overexpression of
Rheb1 led to precocious myelination (Zou et al., 2011).
Akt is the best characterized target of the mTORC2 complex
(Russell et al., 2011). This complex phosphorylates S473 of Akt,
but persistent phosphorylation at this site in the mutant suggests
that either this arises from other cell types in peripheral nerve,
including axons, or the possible involvement of another kinase in
Schwann cells, as has been proposed previously for skeletal and
cardiac muscle (Bentzinger et al., 2008; Risson et al., 2009; Zhang
et al., 2010). Interestingly, it is known that, in a variety of cell
lines, there is enhanced ILK/rictor complex-dependent phos-
phorylation at S473 in the absence of mTOR (McDonald et al.,
2008). Since there is a population of Akt in mutant (but not
control) lysates that is phosphorylated on T308 but not S473, it
seems most likely that this signal arises from Schwann cells and
that normally mTORC2 is primarily responsible for Akt S473
phosphorylation. Enhanced phosphorylation on T308 is likely to
be a consequence of the suppression of the feedback loop, S6K to
AKT 308 via insulin receptor substrate and PI3K (Harrington et
al., 2004; Shah et al., 2004). If elevated Akt S473 phosphorylation
occurs in axons, it will be of interest to explore any possible
relationship to the regulation of neurofilament phosphorylation.
Mutant Schwann cells, with their thin myelin, had a striking ef-
fect on axonal diameter. This was apparent by P21, by which time
75% of the sorted axons in mutant nerves were myelinated. Fur-
ther, the diameters of unmyelinated fibers in 1:1 relationship with
axons at this age exhibited a wide range from 1 to 4m, suggesting
that it was not simply the absence of myelin that caused the overall
reduction in axon diameter. Other hypomyelinating mutants in
mice also display reductions in axon caliber (Robertson et al., 1997;
Frei et al., 1999). Hence, it seems likely that thin myelin sheaths
themselves and the disturbances in axon–glia interactions that they
reflect influence axon growth. Conversely, overproduction of my-
elin in thePTENknock-out results in increasedaxondiameter (Goe-
bbels et al., 2010). Further, it has been proposed that Dlg1, by
influencingPTENactivity,might act as a brake on the productionof
myelin outfoldings and subsequent demyelination (Cotter et al.,
2010).However,mutantswerenotdeficient inDlg1andtheoutfold-
ings that we observed at low frequency did not lead to demyelina-
tion, at least up to 10months of age.
Although highly retarded in mutants, myelin continues to grow
both radially and longitudinally and the relationship between the
thickness of themyelin sheath and the diameter of the axon remains
constant froman early stage. Clearly, it will be of great interest in the
future to determinewhether aberrant transcriptional regulation, for
examplebySREBP,plays apart in thepostnatal arrestofmyelination
weobserved in thePNS. Inviewof themanyregulators andsignaling
pathways that converge on the mTORC complexes, it will also be
important to determine whether as yet incompletely characterized
variants of the inherited peripheral neuropathy, Charcot-Marie-
Tooth disease, present with the arrested myelination phenotype we
describe here.
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